birtamimab

Monoclonal antibody

Discontinuedsponsor decision

Evidence outlook · program status

Discontinued (2025-05), after a negative readout

Phase 3 AFFIRM-AL (NCT04973137) missed its primary endpoint (announced 2025-05-23); Prothena stopped all development. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Other / comorbidity
Phase 2 (4)
Other / comorbidity
NCT03168906 · Tufts Medical Center
2017-07-05 – 2019-02-06 · Amyloidosis
What this study did
NCT03154047 · Prothena Biosciences Ltd.
2017-06-14 – 2018-05-30 · AL Amyloidosis
What this study did
NCT02613182 · Prothena Biosciences Ltd.
2016-02 – 2018-05 · AL Amyloidosis
What this study did
NCT02632786 · Prothena Biosciences Ltd.
2016-03 – 2018-03 · AL Amyloidosis
What this study did
Phase 1/2 (1)
Other / comorbidity

Competitive landscape

This drug's own stage for AL Amyloidosis: Discontinued. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Birtamimab: this drugDiscontinuedMonoclonal antibodyMisfolded immunoglobulin light chain (AL amyloid)not yet gradedNo reviewed efficacy summary in this indication
Anselamimab (Amlypave)Phase 3Monoclonal antibody—not yet gradedNo reviewed efficacy summary in this indication
DaratumumabPhase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
EtentamigPhase 3Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
SCTC21CPhase 3Biologic (subtype unspecified)CD38not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

23 May 2025Topline resultPhase 3 AFFIRM-AL of birtamimab did not meet its primary endpoint
Prothena Biosciences Limited · Source ↗